Targeting Diuretic Resistance in Heart Failure

Phase 1, randomised, open-label trial of chlorothiazide in heart failure (HF) (3 arms), sponsored by Yale University. Primary endpoints: Accuracy of sodium prediction equation in predicting suboptimal natriuretic response to a dose of diuretics at 6 hours, Prevalence of mechanistic sub types of Diuretic Resistance (DR) as defined by cutoff values of change in fractional excretion of lithium at 6 hours and 2 more. Started Aug 2015; status: completed.